[go: up one dir, main page]

DE60206911D1 - Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren - Google Patents

Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren

Info

Publication number
DE60206911D1
DE60206911D1 DE60206911T DE60206911T DE60206911D1 DE 60206911 D1 DE60206911 D1 DE 60206911D1 DE 60206911 T DE60206911 T DE 60206911T DE 60206911 T DE60206911 T DE 60206911T DE 60206911 D1 DE60206911 D1 DE 60206911D1
Authority
DE
Germany
Prior art keywords
kinase inhibitors
raf kinase
imidazole
carboxylamide derivatives
carboxylamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60206911T
Other languages
English (en)
Other versions
DE60206911T2 (de
Inventor
Kenneth Dean
Kenneth TAKLE
Matthew Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of DE60206911D1 publication Critical patent/DE60206911D1/de
Application granted granted Critical
Publication of DE60206911T2 publication Critical patent/DE60206911T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60206911T 2001-05-19 2002-05-20 Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren Expired - Fee Related DE60206911T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0112348.8A GB0112348D0 (en) 2001-05-19 2001-05-19 Compounds
GB0112348 2001-05-19
PCT/GB2002/002353 WO2002094808A1 (en) 2001-05-19 2002-05-20 Imidazole-2-carboxamide derivatives as raf kinase inhibitors

Publications (2)

Publication Number Publication Date
DE60206911D1 true DE60206911D1 (de) 2005-12-01
DE60206911T2 DE60206911T2 (de) 2006-07-20

Family

ID=9915014

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60206911T Expired - Fee Related DE60206911T2 (de) 2001-05-19 2002-05-20 Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren

Country Status (8)

Country Link
US (2) US7282500B2 (de)
EP (1) EP1397354B1 (de)
JP (1) JP2004529967A (de)
AT (1) ATE307810T1 (de)
DE (1) DE60206911T2 (de)
ES (1) ES2248610T3 (de)
GB (1) GB0112348D0 (de)
WO (1) WO2002094808A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020050294A (ko) 1999-11-22 2002-06-26 피터 기딩스 신규화합물
AU2001235838A1 (en) * 2000-03-06 2001-09-17 Smithkline Beecham Plc Imidazol derivatives as raf kinase inhibitors
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
EP1432703A1 (de) * 2001-09-05 2004-06-30 Smithkline Beecham Plc Heterocycle-carboxamide derivate als raf kinase inhibitoren
DK1499311T3 (da) 2002-03-29 2010-03-08 Novartis Vaccines & Diagnostic Substituerede benzaboler og anvendelse deraf som RAF-kinaseinhibitorer
US8299108B2 (en) 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
WO2004087153A2 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
US7423150B2 (en) 2003-10-16 2008-09-09 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of Raf kinase
TW200639163A (en) * 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
CA2609299A1 (en) * 2005-05-20 2006-11-23 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
TW200904816A (en) 2007-06-05 2009-02-01 Takeda Pharmaceutical Fused heterocycle derivatives and use thereof
SG183036A1 (en) 2007-07-17 2012-08-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
EP2181987B9 (de) 2007-08-23 2014-09-03 Takeda Pharmaceutical Company Limited 2-Carbonylaminobenzothiazole und ihre Verwendung zur Vorbeugung und Behandlung von Krebs
EP2184285B1 (de) 2007-08-29 2015-11-04 Takeda Pharmaceutical Company Limited Heterocyclische verbindung und ihre verwendung
EP2265574A1 (de) 2008-02-29 2010-12-29 Array Biopharma, Inc. N-(6-aminopyridin-3-yl)-3-(sulfonamido)benzamidderivate als b-raf-inhibitoren zur behandlung von krebs
TW200940539A (en) 2008-02-29 2009-10-01 Array Biopharma Inc RAF inhibitor compounds and methods of use thereof
US8697874B2 (en) 2008-12-01 2014-04-15 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
US20130018033A1 (en) 2009-08-28 2013-01-17 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
US20120157439A1 (en) 2009-08-28 2012-06-21 Genentech, Inc. Raf inhibitor compounds and methods of use thereof
EP2470532A1 (de) 2009-08-28 2012-07-04 Array Biopharma, Inc. 1h-pyrazolo-[3, 4-b]pyridin-zusammensetzungen zur raf-kinase-hemmung
WO2011025965A1 (en) 2009-08-28 2011-03-03 Genentech, Inc. Raf inhibitor compounds and methods of use thereof
SG178853A1 (en) 2009-08-28 2012-04-27 Array Biopharma Inc Raf inhibitor compounds and methods of use thereof
CA2771893A1 (en) 2009-08-28 2011-03-03 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
MX340392B (es) 2010-02-25 2016-07-06 Dana Farber Cancer Inst Inc Mutaciones del protooncogen de serina/treonina-proteina cinasa b-raf (braf) que confieren resistencia a los inhibidores del protooncogen de serina/treonina-proteina cinasa b-raf.
EP2627650A2 (de) 2010-05-26 2013-08-21 Merck Sharp & Dohme Corp. N-phenyl-imidazol-carboxamid-hemmer von 3-phosphoinositidabhängiger proteinkinase-1
WO2012118492A1 (en) 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
EP3515446B1 (de) 2016-09-19 2023-12-20 Novartis AG Therapeutische kombinationen mit einem raf-hemmer und einem erk-hemmer
DK3618875T3 (da) 2017-05-02 2023-07-10 Novartis Ag Kombinationsterapi omfattende en raf-inhibitor og trametinib
KR102881316B1 (ko) 2019-05-13 2025-11-05 노파르티스 아게 암 치료를 위한 raf 억제제로서의 n-(3-(2-(2-하이드록시에톡시)-6-모르폴리노피리딘-4-일)-4-메틸페닐)-2 (트리플루오로메틸)이소니코틴아미드의 새로운 결정질 형태

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3707475A (en) 1970-11-16 1972-12-26 Pfizer Antiinflammatory imidazoles
US3940486A (en) 1971-05-10 1976-02-24 Ciba-Geigy Corporation Imidazole derivatives in the treatment of pain
US4348404A (en) 1980-07-21 1982-09-07 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl-α-polyfluoroalkyl-1H-imidazole-2-methanamines
DD201677A5 (de) 1980-07-25 1983-08-03 Ciba Geigy Verfahren zur herstellung von trisubstituierten imidazolderivaten
US4735958A (en) 1986-12-22 1988-04-05 Warner-Lambert Company Trans-6-[2-[2-(substituted-phenyl)-3- (or 4-) heteroaryl-5-substituted-1H-pyrrol-1-yl]-ethyl]tetrahydro-4-hydroxy-2H-pyran-2-one inhibitors of cholesterol biosynthesis
US5166214A (en) 1988-12-05 1992-11-24 Du Pont Merck Pharmaceutical Company Use of imidazoles for the treatment of atherosclerosis
US5236917A (en) 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
DE3935514A1 (de) 1989-10-25 1991-05-02 Boehringer Mannheim Gmbh Neue bicyclo-imidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
AU8534291A (en) 1990-08-10 1992-03-02 G.D. Searle & Co. Renal-selective angiotensin ii antagonists for treatment of hypertension
FR2673628B1 (fr) 1991-03-07 1993-07-09 Esteve Labor Dr Procede de preparation de derives d'aryl (ou heteroaryl)-piperazinyl-butyl-azoles.
US5861420A (en) 1991-04-05 1999-01-19 G. D. Searle & Co. N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders
US5179117A (en) 1991-12-20 1993-01-12 Du Pont Merck Pharmaceutical Company Antihypercholesterolemic 2-substituted imidazoles
US5656644A (en) 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
US6008235A (en) 1992-01-13 1999-12-28 Smithkline Beecham Corporation Pyridyl substituted imidazoles
US5310748A (en) 1992-05-11 1994-05-10 The Du Pont Merck Pharmaceutical Company Imidazoles for the treatment of atherosclerosis
US5593991A (en) 1993-07-16 1997-01-14 Adams; Jerry L. Imidazole compounds, use and process of making
WO1995003297A1 (en) 1993-07-21 1995-02-02 Smithkline Beecham Corporation Imidazoles for treating cytokine mediated disease
DE69401486T2 (de) 1993-11-12 1997-04-30 Ishihara Sangyo Kaisha Verfahren zur Herstellung 2-cyanoimidazol Derivate
US5733882A (en) 1994-01-17 1998-03-31 Smithkline Beecham Corporation Retroviral protease inhibitors
US5665753A (en) 1994-03-03 1997-09-09 Smithkline Beecham Corporation Cytokine inhibiting imidazole substituted hydroxamic acid derivatives
US5620999A (en) 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5514505A (en) 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
US6342510B1 (en) 1995-06-12 2002-01-29 G. D. Searle & Co. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitors and a leukotriene B4 receptor antagonist
US5792778A (en) 1995-08-10 1998-08-11 Merck & Co., Inc. 2-substituted aryl pyrroles, compositions containing such compounds and methods of use
US5837719A (en) 1995-08-10 1998-11-17 Merck & Co., Inc. 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
JPH11510511A (ja) 1995-08-10 1999-09-14 メルク エンド カンパニー インコーポレーテッド ２，５−置換アリールピロール、この化合物を含有する組成物及び使用方法
EP0854870B1 (de) 1995-10-06 2009-06-10 Merck & Co., Inc. Substituierte imidazole mit krebsremmender und cytokininhibierender wirkung
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
GB2306108A (en) 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
WO1997016442A1 (en) 1995-10-31 1997-05-09 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
AU7482396A (en) 1995-10-31 1997-05-22 Merck & Co., Inc. Substituted aryl pyrroles, compositions containing such compounds and methods of use
CZ203698A3 (cs) 1995-12-29 1999-05-12 Smithkline Beecham Corporation Antagonista vitronektinového receptoru, farmaceutický přípravek s jeho obsahem, způsob a použití
US6136828A (en) 1996-02-01 2000-10-24 Smithkline Beecham Corporation Endothelin receptor antagonists
WO1997029774A1 (en) 1996-02-13 1997-08-21 G.D. Searle & Co. Combinations, having immunosuppressive effects, containing a cyclooxygenase-2 inhibitor and a leukotriene a4 hydrolase inhibitor
JP2000505445A (ja) 1996-02-13 2000-05-09 ジー．ディー．サール アンド カンパニー シクロオキシゲナーゼ―２インヒビターとロイコトリエンｂ▲下４▼受容体アンタゴニストの投与の免疫抑制作用
JP2000507545A (ja) 1996-03-25 2000-06-20 スミスクライン・ビーチャム・コーポレイション Ｃｎｓ損傷についての新規な治療
WO1997036587A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. A method of treating cancer
EP0906307B1 (de) 1996-06-10 2005-04-27 Merck & Co., Inc. Substituierte imidazole mit cytokinin-inhibirender wirkung
EP0915825B1 (de) 1996-06-21 2004-05-06 Allergan, Inc. Substituierte tetrahydronaphthalin- und dihydronaphthalin-derivate mit einer retinoiden und/oder retinoid antagonist-ähnlichen biologischen aktivität
AU4109297A (en) 1996-09-27 1998-04-17 Merkler, H. Tank for liquids, particularly for chemically aggressive liquids
CN100558356C (zh) 1996-10-15 2009-11-11 G.D.瑟尔公司 应用环加氧酶-2抑制剂治疗和预防肿瘤形成的方法
DE69735811T2 (de) 1996-10-30 2006-12-28 Schering Corp. Piperazinoderivate als neurokinin-antagonisten
US5776954A (en) 1996-10-30 1998-07-07 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
US6180643B1 (en) 1996-11-19 2001-01-30 Amgen Inc. Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents
US5880139A (en) 1996-11-20 1999-03-09 Merck & Co., Inc. Triaryl substituted imidazoles as glucagon antagonists
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
US6608060B1 (en) 1996-12-18 2003-08-19 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US6147080A (en) 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US5945418A (en) 1996-12-18 1999-08-31 Vertex Pharmaceuticals Incorporated Inhibitors of p38
DE69816109T2 (de) 1997-04-24 2004-04-22 Ortho-Mcneil Pharmaceutical, Inc. Substituierte imidazole zur behandlung von entzündlichen krankheiten
WO1998047899A1 (en) 1997-04-24 1998-10-29 Ortho-Mcneil Corporation, Inc. Substituted pyrrolopyridines useful in the treatment of inflammatory diseases
US6979686B1 (en) 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
US6087496A (en) 1998-05-22 2000-07-11 G. D. Searle & Co. Substituted pyrazoles suitable as p38 kinase inhibitors
AR037061A1 (es) 1997-05-22 2004-10-20 Searle & Co Compuesto derivado de pirazol sustituido, procesos para preparar dicho compuesto, composicion farmaceutica que lo contiene y su uso en la preparacion de medicamentos
EP1019394A1 (de) 1997-05-22 2000-07-19 G.D. Searle & Co. PYRAZOLDERIVATE ALS p38-KINASE-INHIBITOREN
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
JP4344960B2 (ja) 1997-05-23 2009-10-14 バイエル、コーポレイション アリール尿素によるｐ３８キナーゼ活性の阻害
SK171099A3 (en) 1997-06-12 2001-12-03 Rhone Poulenc Rorer Ltd Imidazolyl-cyclic acetals
GB9713726D0 (en) 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
US6040320A (en) 1997-06-30 2000-03-21 Ortho-Mcneil Pharmaceutical, Inc. 2-substituted imidazoles useful in the treatment of inflammatory diseases
US5939421A (en) 1997-07-01 1999-08-17 Signal Pharmaceuticals, Inc. Quinazoline analogs and related compounds and methods for treating inflammatory conditions
TR200001079T2 (tr) 1997-10-20 2000-07-21 F.Hoffmann-La Roche Ag Bisiklik kinaz inhibitörleri.
US6436966B1 (en) 1997-10-27 2002-08-20 Takeda Chemical Ind., Ltd. Adenosine A3 receptor antagonists
HUP0004947A2 (hu) 1997-11-14 2002-03-28 Sankyo Co., Ltd. Piridilpirrol-származékok
KR100622138B1 (ko) 1997-12-22 2006-09-13 바이엘 코포레이션 아릴 및 헤테로아릴 치환 헤테로고리형 우레아를 사용한라프 키나제의 저해
PL195808B1 (pl) 1997-12-22 2007-10-31 Bayer Corp Moczniki arylowe, kompozycja je zawierająca i ichzastosowanie
JPH11246437A (ja) 1998-03-05 1999-09-14 Yoshitomi Pharmaceut Ind Ltd 消化管粘膜保護剤
CA2332402A1 (en) 1998-05-22 1999-12-02 Susan B. Dillon Novel 2-alkyl substituted imidazole compounds
BR9911752A (pt) 1998-07-01 2001-04-03 Takeda Chemical Industries Ltd Agente de regulagem da função do receptor relacionado com a retinóide, derivados de oxazol, de imidazol e de tiazol, composto, processo para regular uma função de receptor relacionado com a retinóide, e, uso de um derivado
AU4395399A (en) 1998-07-02 2000-01-24 Sankyo Company Limited Five-membered heteroaryl compounds
DE69935433T2 (de) 1998-07-30 2007-10-25 Point Biomedical Corp., San Carlos Neuer wirkstoffträger für die gefriertrocknung von wässrigen suspensionen von mikropartikeln
US6207687B1 (en) 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
WO2000026209A1 (en) 1998-11-03 2000-05-11 Novartis Ag Anti-inflammatory 4-phenyl-5-pyrimidinyl-imidazoles
JP2002528506A (ja) 1998-11-04 2002-09-03 スミスクライン・ビーチャム・コーポレイション ピリジン−４−イルまたはピリミジン−４−イル置換ピラジン
WO2000034255A1 (en) 1998-12-04 2000-06-15 Ontogen Corporation Substituted thiazoles for treatment of human diseases involving modulators of p-, l- and e- selectin
AU4556800A (en) 1999-04-27 2000-11-10 Smithkline Beecham Plc Novel treatment
WO2001034150A1 (en) 1999-11-12 2001-05-17 Merck & Co., Inc. Aliphatic amine substituted piperidyl diaryl pyrrole derivatives as antiprotozoal agents
NZ518718A (en) 1999-11-12 2004-03-26 Merck & Co Inc Diaryl piperidyl pyrrole derivatives as antiprotozoal agents, treatment or prophylaxis of coccidiosis
KR20020050294A (ko) 1999-11-22 2002-06-26 피터 기딩스 신규화합물
GB0005357D0 (en) 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
AU2001235838A1 (en) 2000-03-06 2001-09-17 Smithkline Beecham Plc Imidazol derivatives as raf kinase inhibitors
US6353336B1 (en) * 2000-03-24 2002-03-05 Cypress Semiconductor Corp. Electrical ID method for output driver
JP2002037784A (ja) 2000-05-17 2002-02-06 Nikken Chem Co Ltd 新規チオフェンアミド化合物
KR20030030027A (ko) 2000-09-21 2003-04-16 스미스클라인비이참피이엘시이 Ｒａｆ 키나제 저해제인 이미다졸 유도체
WO2002039954A2 (en) 2000-11-20 2002-05-23 Smithkline Beecham Corporation Novel compounds
WO2002057255A1 (en) 2001-01-22 2002-07-25 Sankyo Company, Limited 4- or 5-substituted pyrrole derivatives
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
GB0121494D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
ES2309207T3 (es) 2001-09-05 2008-12-16 Smithkline Beecham Plc Derivados furanicos sustituidos con piridina como inhibidores de quinasa raf.
GB0121488D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
GB0121490D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Ciompounds
JP2005505562A (ja) 2001-09-05 2005-02-24 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー Ｒａｆキナーゼ阻害剤としてのピリジルフランおよびピロール
EP1432703A1 (de) 2001-09-05 2004-06-30 Smithkline Beecham Plc Heterocycle-carboxamide derivate als raf kinase inhibitoren
DE10145254A1 (de) 2001-09-13 2003-04-10 November Ag Molekulare Medizin Verwendung eines Proteins zur Herstellung eines Medikaments zur Stimulierung einer inflammatorischen zellulären Immunantwort

Also Published As

Publication number Publication date
WO2002094808A1 (en) 2002-11-28
EP1397354B1 (de) 2005-10-26
JP2004529967A (ja) 2004-09-30
ES2248610T3 (es) 2006-03-16
GB0112348D0 (en) 2001-07-11
ATE307810T1 (de) 2005-11-15
EP1397354A1 (de) 2004-03-17
US7282500B2 (en) 2007-10-16
DE60206911T2 (de) 2006-07-20
US20040127496A1 (en) 2004-07-01
US20080108615A1 (en) 2008-05-08

Similar Documents

Publication Publication Date Title
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
EA200700099A1 (ru) Производные пиридина
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20085217L (no) Effektive pyrimidinderivater i behandlingen av kreft
LTPA2016016I1 (lt) Azetinidai kaip mek inhibitoriai, skirti proliferacinių ligų gydymui
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
ATE452129T1 (de) N-phenyl-2-pyrimidine-amine derivatives
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
DK1678166T3 (da) Proteinkinaseinhibitorer
NO20070514L (no) Pyrrolotriazin kinase inhibitorer
ATE517882T1 (de) Chinolinderivate
EA200700902A1 (ru) 3-ариламинопиридиновые производные
EA200970611A1 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы
NO20061506L (no) Heterocykliske inhibitorer av MEK og fremgangsmater for anvendelse derav
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
EA200501332A1 (ru) Производные пиримидин-4-она и их применение в качестве модуляторов киназы p38
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
EA200701930A1 (ru) Производные пиримидина для лечения гиперпролиферативных нарушений
ATE368040T1 (de) Substituierte tetrazyklische pyprolochinolonderivate als phosphodiesterase- inhibitoren
NO20054361D0 (no) Benzensylfonamidderivater, fremgangsmate for fremstilling og anvendelse derav for behandlig av smerte
MXPA04005809A (es) Inhibidores de proteinas quinasas.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee